

# Global Indolent Lymphoma Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030

<https://marketpublishers.com/r/GA3C654EC56EEN.html>

Date: June 2024

Pages: 106

Price: US\$ 3,480.00 (Single User License)

ID: GA3C654EC56EEN

## Abstracts

According to our (Global Info Research) latest study, the global Indolent Lymphoma Treatment market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The Global Info Research report includes an overview of the development of the Indolent Lymphoma Treatment industry chain, the market status of Hospital (BI-836826, ALT-803), Clinic (BI-836826, ALT-803), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Indolent Lymphoma Treatment.

Regionally, the report analyzes the Indolent Lymphoma Treatment markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Indolent Lymphoma Treatment market, with robust domestic demand, supportive policies, and a strong manufacturing base.

#### Key Features:

The report presents comprehensive understanding of the Indolent Lymphoma Treatment market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Indolent Lymphoma Treatment industry.

The report involves analyzing the market at a macro level:

**Market Sizing and Segmentation:** Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., BI-836826, ALT-803).

**Industry Analysis:** Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Indolent Lymphoma Treatment market.

**Regional Analysis:** The report involves examining the Indolent Lymphoma Treatment market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

**Market Projections:** Report covers the gathered data and analysis to make future projections and forecasts for the Indolent Lymphoma Treatment market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Indolent Lymphoma Treatment:

**Company Analysis:** Report covers individual Indolent Lymphoma Treatment players, suppliers, and other relevant industry players. This analysis includes studying their

financial performance, market positioning, product portfolios, partnerships, and strategies.

**Consumer Analysis:** Report covers data on consumer behaviour, preferences, and attitudes towards Indolent Lymphoma Treatment This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).

**Technology Analysis:** Report covers specific technologies relevant to Indolent Lymphoma Treatment. It assesses the current state, advancements, and potential future developments in Indolent Lymphoma Treatment areas.

**Competitive Landscape:** By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Indolent Lymphoma Treatment market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

**Market Validation:** The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

## Market Segmentation

Indolent Lymphoma Treatment market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

## Market segment by Type

BI-836826

ALT-803

BMS-986016

CC-122

Others

## Market segment by Application

Hospital

Clinic

Others

## Market segment by players, this report covers

Altor BioScience Corporation

Amgen Inc.

Astellas Pharma Inc.

Bayer AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corporation

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

Incyte Corporation

Infinity Pharmaceuticals, Inc.

Juno Therapeutics Inc.

MedImmune, LLC

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Argentina and Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Indolent Lymphoma Treatment product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Indolent Lymphoma Treatment, with revenue, gross margin and global market share of Indolent Lymphoma Treatment from 2019 to 2024.

Chapter 3, the Indolent Lymphoma Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024. and Indolent Lymphoma Treatment market forecast, by regions, type and application, with consumption value, from 2025 to 2030.

Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Indolent Lymphoma Treatment.

Chapter 13, to describe Indolent Lymphoma Treatment research findings and conclusion.

## Contents

### 1 MARKET OVERVIEW

1.1 Product Overview and Scope of Indolent Lymphoma Treatment

1.2 Market Estimation Caveats and Base Year

1.3 Classification of Indolent Lymphoma Treatment by Type

1.3.1 Overview: Global Indolent Lymphoma Treatment Market Size by Type: 2019 Versus 2023 Versus 2030

1.3.2 Global Indolent Lymphoma Treatment Consumption Value Market Share by Type in 2023

1.3.3 BI-836826

1.3.4 ALT-803

1.3.5 BMS-986016

1.3.6 CC-122

1.3.7 Others

1.4 Global Indolent Lymphoma Treatment Market by Application

1.4.1 Overview: Global Indolent Lymphoma Treatment Market Size by Application: 2019 Versus 2023 Versus 2030

1.4.2 Hospital

1.4.3 Clinic

1.4.4 Others

1.5 Global Indolent Lymphoma Treatment Market Size & Forecast

1.6 Global Indolent Lymphoma Treatment Market Size and Forecast by Region

1.6.1 Global Indolent Lymphoma Treatment Market Size by Region: 2019 VS 2023 VS 2030

1.6.2 Global Indolent Lymphoma Treatment Market Size by Region, (2019-2030)

1.6.3 North America Indolent Lymphoma Treatment Market Size and Prospect (2019-2030)

1.6.4 Europe Indolent Lymphoma Treatment Market Size and Prospect (2019-2030)

1.6.5 Asia-Pacific Indolent Lymphoma Treatment Market Size and Prospect (2019-2030)

1.6.6 South America Indolent Lymphoma Treatment Market Size and Prospect (2019-2030)

1.6.7 Middle East and Africa Indolent Lymphoma Treatment Market Size and Prospect (2019-2030)

### 2 COMPANY PROFILES

## 2.1 Altor BioScience Corporation

2.1.1 Altor BioScience Corporation Details

2.1.2 Altor BioScience Corporation Major Business

2.1.3 Altor BioScience Corporation Indolent Lymphoma Treatment Product and Solutions

2.1.4 Altor BioScience Corporation Indolent Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.1.5 Altor BioScience Corporation Recent Developments and Future Plans

## 2.2 Amgen Inc.

2.2.1 Amgen Inc. Details

2.2.2 Amgen Inc. Major Business

2.2.3 Amgen Inc. Indolent Lymphoma Treatment Product and Solutions

2.2.4 Amgen Inc. Indolent Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.2.5 Amgen Inc. Recent Developments and Future Plans

## 2.3 Astellas Pharma Inc.

2.3.1 Astellas Pharma Inc. Details

2.3.2 Astellas Pharma Inc. Major Business

2.3.3 Astellas Pharma Inc. Indolent Lymphoma Treatment Product and Solutions

2.3.4 Astellas Pharma Inc. Indolent Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.3.5 Astellas Pharma Inc. Recent Developments and Future Plans

## 2.4 Bayer AG

2.4.1 Bayer AG Details

2.4.2 Bayer AG Major Business

2.4.3 Bayer AG Indolent Lymphoma Treatment Product and Solutions

2.4.4 Bayer AG Indolent Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.4.5 Bayer AG Recent Developments and Future Plans

## 2.5 Boehringer Ingelheim GmbH

2.5.1 Boehringer Ingelheim GmbH Details

2.5.2 Boehringer Ingelheim GmbH Major Business

2.5.3 Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Product and Solutions

2.5.4 Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.5.5 Boehringer Ingelheim GmbH Recent Developments and Future Plans

## 2.6 Bristol-Myers Squibb Company

2.6.1 Bristol-Myers Squibb Company Details



- 2.6.2 Bristol-Myers Squibb Company Major Business
- 2.6.3 Bristol-Myers Squibb Company Indolent Lymphoma Treatment Product and Solutions
- 2.6.4 Bristol-Myers Squibb Company Indolent Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.6.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
- 2.7 Celgene Corporation
  - 2.7.1 Celgene Corporation Details
  - 2.7.2 Celgene Corporation Major Business
  - 2.7.3 Celgene Corporation Indolent Lymphoma Treatment Product and Solutions
  - 2.7.4 Celgene Corporation Indolent Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
  - 2.7.5 Celgene Corporation Recent Developments and Future Plans
- 2.8 Eli Lilly and Company
  - 2.8.1 Eli Lilly and Company Details
  - 2.8.2 Eli Lilly and Company Major Business
  - 2.8.3 Eli Lilly and Company Indolent Lymphoma Treatment Product and Solutions
  - 2.8.4 Eli Lilly and Company Indolent Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
  - 2.8.5 Eli Lilly and Company Recent Developments and Future Plans
- 2.9 F. Hoffmann-La Roche Ltd.
  - 2.9.1 F. Hoffmann-La Roche Ltd. Details
  - 2.9.2 F. Hoffmann-La Roche Ltd. Major Business
  - 2.9.3 F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Product and Solutions
  - 2.9.4 F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
  - 2.9.5 F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
- 2.10 Gilead Sciences, Inc.
  - 2.10.1 Gilead Sciences, Inc. Details
  - 2.10.2 Gilead Sciences, Inc. Major Business
  - 2.10.3 Gilead Sciences, Inc. Indolent Lymphoma Treatment Product and Solutions
  - 2.10.4 Gilead Sciences, Inc. Indolent Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
  - 2.10.5 Gilead Sciences, Inc. Recent Developments and Future Plans
- 2.11 Incyte Corporation
  - 2.11.1 Incyte Corporation Details
  - 2.11.2 Incyte Corporation Major Business
  - 2.11.3 Incyte Corporation Indolent Lymphoma Treatment Product and Solutions

2.11.4 Incyte Corporation Indolent Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.11.5 Incyte Corporation Recent Developments and Future Plans

2.12 Infinity Pharmaceuticals, Inc.

2.12.1 Infinity Pharmaceuticals, Inc. Details

2.12.2 Infinity Pharmaceuticals, Inc. Major Business

2.12.3 Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Product and Solutions

2.12.4 Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.12.5 Infinity Pharmaceuticals, Inc. Recent Developments and Future Plans

2.13 Juno Therapeutics Inc.

2.13.1 Juno Therapeutics Inc. Details

2.13.2 Juno Therapeutics Inc. Major Business

2.13.3 Juno Therapeutics Inc. Indolent Lymphoma Treatment Product and Solutions

2.13.4 Juno Therapeutics Inc. Indolent Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.13.5 Juno Therapeutics Inc. Recent Developments and Future Plans

2.14 MedImmune, LLC

2.14.1 MedImmune, LLC Details

2.14.2 MedImmune, LLC Major Business

2.14.3 MedImmune, LLC Indolent Lymphoma Treatment Product and Solutions

2.14.4 MedImmune, LLC Indolent Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.14.5 MedImmune, LLC Recent Developments and Future Plans

### **3 MARKET COMPETITION, BY PLAYERS**

3.1 Global Indolent Lymphoma Treatment Revenue and Share by Players (2019-2024)

3.2 Market Share Analysis (2023)

3.2.1 Market Share of Indolent Lymphoma Treatment by Company Revenue

3.2.2 Top 3 Indolent Lymphoma Treatment Players Market Share in 2023

3.2.3 Top 6 Indolent Lymphoma Treatment Players Market Share in 2023

3.3 Indolent Lymphoma Treatment Market: Overall Company Footprint Analysis

3.3.1 Indolent Lymphoma Treatment Market: Region Footprint

3.3.2 Indolent Lymphoma Treatment Market: Company Product Type Footprint

3.3.3 Indolent Lymphoma Treatment Market: Company Product Application Footprint

3.4 New Market Entrants and Barriers to Market Entry

3.5 Mergers, Acquisition, Agreements, and Collaborations

## **4 MARKET SIZE SEGMENT BY TYPE**

4.1 Global Indolent Lymphoma Treatment Consumption Value and Market Share by Type (2019-2024)

4.2 Global Indolent Lymphoma Treatment Market Forecast by Type (2025-2030)

## **5 MARKET SIZE SEGMENT BY APPLICATION**

5.1 Global Indolent Lymphoma Treatment Consumption Value Market Share by Application (2019-2024)

5.2 Global Indolent Lymphoma Treatment Market Forecast by Application (2025-2030)

## **6 NORTH AMERICA**

6.1 North America Indolent Lymphoma Treatment Consumption Value by Type (2019-2030)

6.2 North America Indolent Lymphoma Treatment Consumption Value by Application (2019-2030)

6.3 North America Indolent Lymphoma Treatment Market Size by Country

6.3.1 North America Indolent Lymphoma Treatment Consumption Value by Country (2019-2030)

6.3.2 United States Indolent Lymphoma Treatment Market Size and Forecast (2019-2030)

6.3.3 Canada Indolent Lymphoma Treatment Market Size and Forecast (2019-2030)

6.3.4 Mexico Indolent Lymphoma Treatment Market Size and Forecast (2019-2030)

## **7 EUROPE**

7.1 Europe Indolent Lymphoma Treatment Consumption Value by Type (2019-2030)

7.2 Europe Indolent Lymphoma Treatment Consumption Value by Application (2019-2030)

7.3 Europe Indolent Lymphoma Treatment Market Size by Country

7.3.1 Europe Indolent Lymphoma Treatment Consumption Value by Country (2019-2030)

7.3.2 Germany Indolent Lymphoma Treatment Market Size and Forecast (2019-2030)

7.3.3 France Indolent Lymphoma Treatment Market Size and Forecast (2019-2030)

7.3.4 United Kingdom Indolent Lymphoma Treatment Market Size and Forecast (2019-2030)

7.3.5 Russia Indolent Lymphoma Treatment Market Size and Forecast (2019-2030)

7.3.6 Italy Indolent Lymphoma Treatment Market Size and Forecast (2019-2030)

## **8 ASIA-PACIFIC**

8.1 Asia-Pacific Indolent Lymphoma Treatment Consumption Value by Type (2019-2030)

8.2 Asia-Pacific Indolent Lymphoma Treatment Consumption Value by Application (2019-2030)

8.3 Asia-Pacific Indolent Lymphoma Treatment Market Size by Region

8.3.1 Asia-Pacific Indolent Lymphoma Treatment Consumption Value by Region (2019-2030)

8.3.2 China Indolent Lymphoma Treatment Market Size and Forecast (2019-2030)

8.3.3 Japan Indolent Lymphoma Treatment Market Size and Forecast (2019-2030)

8.3.4 South Korea Indolent Lymphoma Treatment Market Size and Forecast (2019-2030)

8.3.5 India Indolent Lymphoma Treatment Market Size and Forecast (2019-2030)

8.3.6 Southeast Asia Indolent Lymphoma Treatment Market Size and Forecast (2019-2030)

8.3.7 Australia Indolent Lymphoma Treatment Market Size and Forecast (2019-2030)

## **9 SOUTH AMERICA**

9.1 South America Indolent Lymphoma Treatment Consumption Value by Type (2019-2030)

9.2 South America Indolent Lymphoma Treatment Consumption Value by Application (2019-2030)

9.3 South America Indolent Lymphoma Treatment Market Size by Country

9.3.1 South America Indolent Lymphoma Treatment Consumption Value by Country (2019-2030)

9.3.2 Brazil Indolent Lymphoma Treatment Market Size and Forecast (2019-2030)

9.3.3 Argentina Indolent Lymphoma Treatment Market Size and Forecast (2019-2030)

## **10 MIDDLE EAST & AFRICA**

10.1 Middle East & Africa Indolent Lymphoma Treatment Consumption Value by Type (2019-2030)

10.2 Middle East & Africa Indolent Lymphoma Treatment Consumption Value by Application (2019-2030)

### 10.3 Middle East & Africa Indolent Lymphoma Treatment Market Size by Country

10.3.1 Middle East & Africa Indolent Lymphoma Treatment Consumption Value by Country (2019-2030)

10.3.2 Turkey Indolent Lymphoma Treatment Market Size and Forecast (2019-2030)

10.3.3 Saudi Arabia Indolent Lymphoma Treatment Market Size and Forecast (2019-2030)

10.3.4 UAE Indolent Lymphoma Treatment Market Size and Forecast (2019-2030)

## 11 MARKET DYNAMICS

11.1 Indolent Lymphoma Treatment Market Drivers

11.2 Indolent Lymphoma Treatment Market Restraints

11.3 Indolent Lymphoma Treatment Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

## 12 INDUSTRY CHAIN ANALYSIS

12.1 Indolent Lymphoma Treatment Industry Chain

12.2 Indolent Lymphoma Treatment Upstream Analysis

12.3 Indolent Lymphoma Treatment Midstream Analysis

12.4 Indolent Lymphoma Treatment Downstream Analysis

## 13 RESEARCH FINDINGS AND CONCLUSION

## 14 APPENDIX

14.1 Methodology

14.2 Research Process and Data Source

14.3 Disclaimer

## List Of Tables

### LIST OF TABLES

- Table 1. Global Indolent Lymphoma Treatment Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
- Table 2. Global Indolent Lymphoma Treatment Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
- Table 3. Global Indolent Lymphoma Treatment Consumption Value by Region (2019-2024) & (USD Million)
- Table 4. Global Indolent Lymphoma Treatment Consumption Value by Region (2025-2030) & (USD Million)
- Table 5. Altor BioScience Corporation Company Information, Head Office, and Major Competitors
- Table 6. Altor BioScience Corporation Major Business
- Table 7. Altor BioScience Corporation Indolent Lymphoma Treatment Product and Solutions
- Table 8. Altor BioScience Corporation Indolent Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 9. Altor BioScience Corporation Recent Developments and Future Plans
- Table 10. Amgen Inc. Company Information, Head Office, and Major Competitors
- Table 11. Amgen Inc. Major Business
- Table 12. Amgen Inc. Indolent Lymphoma Treatment Product and Solutions
- Table 13. Amgen Inc. Indolent Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 14. Amgen Inc. Recent Developments and Future Plans
- Table 15. Astellas Pharma Inc. Company Information, Head Office, and Major Competitors
- Table 16. Astellas Pharma Inc. Major Business
- Table 17. Astellas Pharma Inc. Indolent Lymphoma Treatment Product and Solutions
- Table 18. Astellas Pharma Inc. Indolent Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 19. Astellas Pharma Inc. Recent Developments and Future Plans
- Table 20. Bayer AG Company Information, Head Office, and Major Competitors
- Table 21. Bayer AG Major Business
- Table 22. Bayer AG Indolent Lymphoma Treatment Product and Solutions
- Table 23. Bayer AG Indolent Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 24. Bayer AG Recent Developments and Future Plans

- Table 25. Boehringer Ingelheim GmbH Company Information, Head Office, and Major Competitors
- Table 26. Boehringer Ingelheim GmbH Major Business
- Table 27. Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Product and Solutions
- Table 28. Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 29. Boehringer Ingelheim GmbH Recent Developments and Future Plans
- Table 30. Bristol-Myers Squibb Company Company Information, Head Office, and Major Competitors
- Table 31. Bristol-Myers Squibb Company Major Business
- Table 32. Bristol-Myers Squibb Company Indolent Lymphoma Treatment Product and Solutions
- Table 33. Bristol-Myers Squibb Company Indolent Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 34. Bristol-Myers Squibb Company Recent Developments and Future Plans
- Table 35. Celgene Corporation Company Information, Head Office, and Major Competitors
- Table 36. Celgene Corporation Major Business
- Table 37. Celgene Corporation Indolent Lymphoma Treatment Product and Solutions
- Table 38. Celgene Corporation Indolent Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 39. Celgene Corporation Recent Developments and Future Plans
- Table 40. Eli Lilly and Company Company Information, Head Office, and Major Competitors
- Table 41. Eli Lilly and Company Major Business
- Table 42. Eli Lilly and Company Indolent Lymphoma Treatment Product and Solutions
- Table 43. Eli Lilly and Company Indolent Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 44. Eli Lilly and Company Recent Developments and Future Plans
- Table 45. F. Hoffmann-La Roche Ltd. Company Information, Head Office, and Major Competitors
- Table 46. F. Hoffmann-La Roche Ltd. Major Business
- Table 47. F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Product and Solutions
- Table 48. F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 49. F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
- Table 50. Gilead Sciences, Inc. Company Information, Head Office, and Major

## Competitors

Table 51. Gilead Sciences, Inc. Major Business

Table 52. Gilead Sciences, Inc. Indolent Lymphoma Treatment Product and Solutions

Table 53. Gilead Sciences, Inc. Indolent Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 54. Gilead Sciences, Inc. Recent Developments and Future Plans

Table 55. Incyte Corporation Company Information, Head Office, and Major Competitors

Table 56. Incyte Corporation Major Business

Table 57. Incyte Corporation Indolent Lymphoma Treatment Product and Solutions

Table 58. Incyte Corporation Indolent Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 59. Incyte Corporation Recent Developments and Future Plans

Table 60. Infinity Pharmaceuticals, Inc. Company Information, Head Office, and Major Competitors

Table 61. Infinity Pharmaceuticals, Inc. Major Business

Table 62. Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Product and Solutions

Table 63. Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 64. Infinity Pharmaceuticals, Inc. Recent Developments and Future Plans

Table 65. Juno Therapeutics Inc. Company Information, Head Office, and Major Competitors

Table 66. Juno Therapeutics Inc. Major Business

Table 67. Juno Therapeutics Inc. Indolent Lymphoma Treatment Product and Solutions

Table 68. Juno Therapeutics Inc. Indolent Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 69. Juno Therapeutics Inc. Recent Developments and Future Plans

Table 70. MedImmune, LLC Company Information, Head Office, and Major Competitors

Table 71. MedImmune, LLC Major Business

Table 72. MedImmune, LLC Indolent Lymphoma Treatment Product and Solutions

Table 73. MedImmune, LLC Indolent Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 74. MedImmune, LLC Recent Developments and Future Plans

Table 75. Global Indolent Lymphoma Treatment Revenue (USD Million) by Players (2019-2024)

Table 76. Global Indolent Lymphoma Treatment Revenue Share by Players (2019-2024)

Table 77. Breakdown of Indolent Lymphoma Treatment by Company Type (Tier 1, Tier 2, and Tier 3)



Table 78. Market Position of Players in Indolent Lymphoma Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023

Table 79. Head Office of Key Indolent Lymphoma Treatment Players

Table 80. Indolent Lymphoma Treatment Market: Company Product Type Footprint

Table 81. Indolent Lymphoma Treatment Market: Company Product Application Footprint

Table 82. Indolent Lymphoma Treatment New Market Entrants and Barriers to Market Entry

Table 83. Indolent Lymphoma Treatment Mergers, Acquisition, Agreements, and Collaborations

Table 84. Global Indolent Lymphoma Treatment Consumption Value (USD Million) by Type (2019-2024)

Table 85. Global Indolent Lymphoma Treatment Consumption Value Share by Type (2019-2024)

Table 86. Global Indolent Lymphoma Treatment Consumption Value Forecast by Type (2025-2030)

Table 87. Global Indolent Lymphoma Treatment Consumption Value by Application (2019-2024)

Table 88. Global Indolent Lymphoma Treatment Consumption Value Forecast by Application (2025-2030)

Table 89. North America Indolent Lymphoma Treatment Consumption Value by Type (2019-2024) & (USD Million)

Table 90. North America Indolent Lymphoma Treatment Consumption Value by Type (2025-2030) & (USD Million)

Table 91. North America Indolent Lymphoma Treatment Consumption Value by Application (2019-2024) & (USD Million)

Table 92. North America Indolent Lymphoma Treatment Consumption Value by Application (2025-2030) & (USD Million)

Table 93. North America Indolent Lymphoma Treatment Consumption Value by Country (2019-2024) & (USD Million)

Table 94. North America Indolent Lymphoma Treatment Consumption Value by Country (2025-2030) & (USD Million)

Table 95. Europe Indolent Lymphoma Treatment Consumption Value by Type (2019-2024) & (USD Million)

Table 96. Europe Indolent Lymphoma Treatment Consumption Value by Type (2025-2030) & (USD Million)

Table 97. Europe Indolent Lymphoma Treatment Consumption Value by Application (2019-2024) & (USD Million)

Table 98. Europe Indolent Lymphoma Treatment Consumption Value by Application

(2025-2030) & (USD Million)

Table 99. Europe Indolent Lymphoma Treatment Consumption Value by Country (2019-2024) & (USD Million)

Table 100. Europe Indolent Lymphoma Treatment Consumption Value by Country (2025-2030) & (USD Million)

Table 101. Asia-Pacific Indolent Lymphoma Treatment Consumption Value by Type (2019-2024) & (USD Million)

Table 102. Asia-Pacific Indolent Lymphoma Treatment Consumption Value by Type (2025-2030) & (USD Million)

Table 103. Asia-Pacific Indolent Lymphoma Treatment Consumption Value by Application (2019-2024) & (USD Million)

Table 104. Asia-Pacific Indolent Lymphoma Treatment Consumption Value by Application (2025-2030) & (USD Million)

Table 105. Asia-Pacific Indolent Lymphoma Treatment Consumption Value by Region (2019-2024) & (USD Million)

Table 106. Asia-Pacific Indolent Lymphoma Treatment Consumption Value by Region (2025-2030) & (USD Million)

Table 107. South America Indolent Lymphoma Treatment Consumption Value by Type (2019-2024) & (USD Million)

Table 108. South America Indolent Lymphoma Treatment Consumption Value by Type (2025-2030) & (USD Million)

Table 109. South America Indolent Lymphoma Treatment Consumption Value by Application (2019-2024) & (USD Million)

Table 110. South America Indolent Lymphoma Treatment Consumption Value by Application (2025-2030) & (USD Million)

Table 111. South America Indolent Lymphoma Treatment Consumption Value by Country (2019-2024) & (USD Million)

Table 112. South America Indolent Lymphoma Treatment Consumption Value by Country (2025-2030) & (USD Million)

Table 113. Middle East & Africa Indolent Lymphoma Treatment Consumption Value by Type (2019-2024) & (USD Million)

Table 114. Middle East & Africa Indolent Lymphoma Treatment Consumption Value by Type (2025-2030) & (USD Million)

Table 115. Middle East & Africa Indolent Lymphoma Treatment Consumption Value by Application (2019-2024) & (USD Million)

Table 116. Middle East & Africa Indolent Lymphoma Treatment Consumption Value by Application (2025-2030) & (USD Million)

Table 117. Middle East & Africa Indolent Lymphoma Treatment Consumption Value by Country (2019-2024) & (USD Million)

Table 118. Middle East & Africa Indolent Lymphoma Treatment Consumption Value by Country (2025-2030) & (USD Million)

Table 119. Indolent Lymphoma Treatment Raw Material

Table 120. Key Suppliers of Indolent Lymphoma Treatment Raw Materials

## List Of Figures

### LIST OF FIGURES

Figure 1. Indolent Lymphoma Treatment Picture

Figure 2. Global Indolent Lymphoma Treatment Consumption Value by Type, (USD Million), 2019 & 2023 & 2030

Figure 3. Global Indolent Lymphoma Treatment Consumption Value Market Share by Type in 2023

Figure 4. BI-836826

Figure 5. ALT-803

Figure 6. BMS-986016

Figure 7. CC-122

Figure 8. Others

Figure 9. Global Indolent Lymphoma Treatment Consumption Value by Type, (USD Million), 2019 & 2023 & 2030

Figure 10. Indolent Lymphoma Treatment Consumption Value Market Share by Application in 2023

Figure 11. Hospital Picture

Figure 12. Clinic Picture

Figure 13. Others Picture

Figure 14. Global Indolent Lymphoma Treatment Consumption Value, (USD Million): 2019 & 2023 & 2030

Figure 15. Global Indolent Lymphoma Treatment Consumption Value and Forecast (2019-2030) & (USD Million)

Figure 16. Global Market Indolent Lymphoma Treatment Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)

Figure 17. Global Indolent Lymphoma Treatment Consumption Value Market Share by Region (2019-2030)

Figure 18. Global Indolent Lymphoma Treatment Consumption Value Market Share by Region in 2023

Figure 19. North America Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 20. Europe Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 21. Asia-Pacific Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 22. South America Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 23. Middle East and Africa Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 24. Global Indolent Lymphoma Treatment Revenue Share by Players in 2023

Figure 25. Indolent Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023

Figure 26. Global Top 3 Players Indolent Lymphoma Treatment Market Share in 2023

Figure 27. Global Top 6 Players Indolent Lymphoma Treatment Market Share in 2023

Figure 28. Global Indolent Lymphoma Treatment Consumption Value Share by Type (2019-2024)

Figure 29. Global Indolent Lymphoma Treatment Market Share Forecast by Type (2025-2030)

Figure 30. Global Indolent Lymphoma Treatment Consumption Value Share by Application (2019-2024)

Figure 31. Global Indolent Lymphoma Treatment Market Share Forecast by Application (2025-2030)

Figure 32. North America Indolent Lymphoma Treatment Consumption Value Market Share by Type (2019-2030)

Figure 33. North America Indolent Lymphoma Treatment Consumption Value Market Share by Application (2019-2030)

Figure 34. North America Indolent Lymphoma Treatment Consumption Value Market Share by Country (2019-2030)

Figure 35. United States Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 36. Canada Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 37. Mexico Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 38. Europe Indolent Lymphoma Treatment Consumption Value Market Share by Type (2019-2030)

Figure 39. Europe Indolent Lymphoma Treatment Consumption Value Market Share by Application (2019-2030)

Figure 40. Europe Indolent Lymphoma Treatment Consumption Value Market Share by Country (2019-2030)

Figure 41. Germany Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 42. France Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 43. United Kingdom Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 44. Russia Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 45. Italy Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 46. Asia-Pacific Indolent Lymphoma Treatment Consumption Value Market Share by Type (2019-2030)

Figure 47. Asia-Pacific Indolent Lymphoma Treatment Consumption Value Market Share by Application (2019-2030)

Figure 48. Asia-Pacific Indolent Lymphoma Treatment Consumption Value Market Share by Region (2019-2030)

Figure 49. China Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 50. Japan Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 51. South Korea Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 52. India Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 53. Southeast Asia Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 54. Australia Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 55. South America Indolent Lymphoma Treatment Consumption Value Market Share by Type (2019-2030)

Figure 56. South America Indolent Lymphoma Treatment Consumption Value Market Share by Application (2019-2030)

Figure 57. South America Indolent Lymphoma Treatment Consumption Value Market Share by Country (2019-2030)

Figure 58. Brazil Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 59. Argentina Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 60. Middle East and Africa Indolent Lymphoma Treatment Consumption Value Market Share by Type (2019-2030)

Figure 61. Middle East and Africa Indolent Lymphoma Treatment Consumption Value Market Share by Application (2019-2030)

Figure 62. Middle East and Africa Indolent Lymphoma Treatment Consumption Value Market Share by Country (2019-2030)

Figure 63. Turkey Indolent Lymphoma Treatment Consumption Value (2019-2030) &

(USD Million)

Figure 64. Saudi Arabia Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 65. UAE Indolent Lymphoma Treatment Consumption Value (2019-2030) & (USD Million)

Figure 66. Indolent Lymphoma Treatment Market Drivers

Figure 67. Indolent Lymphoma Treatment Market Restraints

Figure 68. Indolent Lymphoma Treatment Market Trends

Figure 69. Porters Five Forces Analysis

Figure 70. Manufacturing Cost Structure Analysis of Indolent Lymphoma Treatment in 2023

Figure 71. Manufacturing Process Analysis of Indolent Lymphoma Treatment

Figure 72. Indolent Lymphoma Treatment Industrial Chain

Figure 73. Methodology

Figure 74. Research Process and Data Source

## I would like to order

Product name: Global Indolent Lymphoma Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Product link: <https://marketpublishers.com/r/GA3C654EC56EEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA3C654EC56EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



